PFKFB3 and atherosclerosis: Another factor that might explain the lack of effect on atherosclerosis compared to studies utilizing 3PO treatment, is recent evidence that 3PO inhibits glycolysis through intracellular acidification, rather than specific PFKFB3 inhibition (Burmistrova et al., 2019; Emini Veseli et al., 2020).